Short answer
Edwards Lifesciences (EW) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1.7B (up 13.6% year over year) with net income of $242M.
Q2 2026 key financials · XBRL
- Revenue
- $1.7B
- +13.6% YoY · +5.6% QoQ
- Net income
- $242M
- −27.4% YoY · −36.5% QoQ
- Operating margin
- 29.5%
- Gross margin
- 77.5%
- EPS (diluted)
- $0.41
- −28.1% YoY · −37.9% QoQ
Source: XBRL data from the Edwards Lifesciences (EW) Q2 2026 10-Q on SEC EDGAR. USD.
Edwards Lifesciences Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, cash flow, cash position, or capital deployment figures provided
- Forward-looking risks: competition, manufacturing issues, reimbursement reductions, cybersecurity, and Critical Care sale
Risk Factors
- No material changes to risk factors from the December 31, 2025 Form 10-K
- Regulatory and compliance risks remain those disclosed in the 2025 Form 10-K
- Operational and competitive risks remain those disclosed in the 2025 Form 10-K
- Financial risks remain those disclosed in the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Edwards Lifesciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.